Tuesday, August 26 09:44:15
Drug developer Kite Pharma Inc said its experimental cancer therapy showed potential in treating patients in an early-stage study.
The company's lead drug, KTE-C19, is being developed to fight an aggressive form of blood cancer.
The immunotherapy involves genetically modifying a patient's cells to target a protein found on the surface of some lymphoma and leukemia cells.
Kite's shares were up 35.2 percent at $30.15 in extended trading. (Reuters)
For more visit: www.businessworld.ie